{"title":"Development of nanoparticles for the Novel anticancer therapeutic agents for Acute Myeloid Leukemia","authors":"Ajay Bhagwat, Rohit Doke Doke, Santosh Ghule, Bipin Gandhi","doi":"10.37285/ijpsn.2023.16.4.7","DOIUrl":null,"url":null,"abstract":"Acute myeloid leukaemia is becoming more predominant in blood cancer in geriatrics people groups. In 2017, four new therapeutic candidates have been approved by the FDA: Enasidenib, CPX 351, Midostaurin, and Gemtuzumab ozogamicin; with the approval of Venetoclax and Daurismo, additional advances were achieved in 2018. Ivosidenib and gilteritinib were also accepted as single-agent therapy in persistent and recurrent AML 2018. Most of the anticancer drugs belong to Biopharmaceutical classification system-II (BSC), and BCS class-IV has poor bioavailability because of solubility issues. We will overcome this problem by preparing nanoparticles of this drug by using different nanoparticle preparation methods.","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"39 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical Sciences and Nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37285/ijpsn.2023.16.4.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Acute myeloid leukaemia is becoming more predominant in blood cancer in geriatrics people groups. In 2017, four new therapeutic candidates have been approved by the FDA: Enasidenib, CPX 351, Midostaurin, and Gemtuzumab ozogamicin; with the approval of Venetoclax and Daurismo, additional advances were achieved in 2018. Ivosidenib and gilteritinib were also accepted as single-agent therapy in persistent and recurrent AML 2018. Most of the anticancer drugs belong to Biopharmaceutical classification system-II (BSC), and BCS class-IV has poor bioavailability because of solubility issues. We will overcome this problem by preparing nanoparticles of this drug by using different nanoparticle preparation methods.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
